Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS.

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a functional gastrointestinal (GI) disorder, defined by the presence of loose stools and abdominal pain. In search for a novel anti-IBS-D therapy, here we investigated the nociceptin receptor (NOP)-dependent effects in the GI tract.
A novel potent and selective NOP agonist SCH 221510 was used in the study. The effect of NOP activation on mouse intestinal motility was characterized in vitro and in vivo, in physiological conditions and in animal models of hypermotility and diarrhea. Well-established mouse models of visceral pain were used to characterize the antinociceptive effect of the NOP activation. To provide additional evidence that the endogenous nociceptin system is a relevant target for IBS, NOP expression and nociceptin levels were quantified in serum and colonic biopsies from IBS-D patients.
SCH 221510 produced a potent NOP-mediated inhibitory effect on mouse intestinal motility in vitro and in vivo in physiological conditions. The NOP agonist displayed an antidiarrheal and analgesic action after oral administration in animal models mimicking the symptoms of IBS-D. Studies on human samples revealed a strong decrease in endogenous nociceptin system expression in IBS-D patients compared with healthy controls.
Collectively, mouse and human data suggest that the endogenous nociceptin system is involved in IBS-D and may become a target for anti-IBS-D treatments using potent and selective synthetic NOP agonists.
AuthorsJ Fichna, M Sobczak, A Mokrowiecka, A I Cygankiewicz, P K Zakrzewski, N Cenac, M Sałaga, J-P Timmermans, N Vergnolle, E Małecka-Panas, W M Krajewska, M Storr
JournalNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (Neurogastroenterol Motil) Vol. 26 Issue 11 Pg. 1539-50 (Nov 2014) ISSN: 1365-2982 [Electronic] England
PMID25041572 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 John Wiley & Sons Ltd.
Chemical References
  • 8-(bis(2-methylphenyl)methyl)-3-phenyl-8-azabicyclo(3.2.1)octan-3-ol
  • Azabicyclo Compounds
  • Opioid Peptides
  • Receptors, Opioid
  • nociceptin
  • nociceptin receptor
  • Animals
  • Azabicyclo Compounds (pharmacology)
  • Diarrhea (etiology)
  • Disease Models, Animal
  • Gastrointestinal Motility (drug effects)
  • Humans
  • Immunohistochemistry
  • Intestines (drug effects, metabolism)
  • Irritable Bowel Syndrome (metabolism)
  • Male
  • Mice
  • Opioid Peptides (metabolism)
  • Pain (metabolism)
  • Real-Time Polymerase Chain Reaction
  • Receptors, Opioid (agonists)
  • Reverse Transcriptase Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: